儿童药品市场－全球产业规模、份额、趋势、机会及预测（按类型、给药途径、最终用户、地区和竞争格局划分，2021-2031年）

全球儿童药品市场预计将从 2025 年的 1,394.6 亿美元成长到 2031 年的 1,941.6 亿美元，复合年增长率为 5.67%。

此细分市场涵盖专为0至18岁婴幼儿、儿童及青少年研发并核准的药物製剂。推动该市场发展的主要因素是青少年慢性病和感染疾病率的上升，这使得人们迫切需要专门的治疗性介入，而不是依赖成人药物的仿单标示外用药。此外，完善的法规结构和法律奖励积极鼓励製药公司优先进行儿童临床试验，从而确保了适龄治疗方法的持续开发平臺。

儘管取得了这些进展，医药产业仍面临着与供应链脆弱性和生产不稳定性相关的重大挑战，这些挑战常常阻碍患者获得医疗服务。这些物流问题往往导致基本药物严重短缺，使脆弱的儿童患者的治疗通讯协定更加复杂。为了说明这些基础设施挑战的严重性，美国卫生系统药剂师协会 (ASHP) 报告称，2024 年第一季出现了创纪录的 323 种药物短缺。如此广泛的供不应求对该行业稳定构成严重威胁，并可能显着阻碍整体市场扩张。

市场驱动因素

儿童慢性病和感染疾病发生率的上升是推动全球儿童药品市场成长的主要因素。疾病负担的转变促使人们对儿童独特生理需求的医疗产品产生需求。随着可预防感染疾病的再次出现，这种需求尤其明显，促使医疗系统采购针对儿童的疫苗和治疗药物。例如，世界卫生组织（WHO）和美国疾病管制与预防中心（CDC）于2024年11月联合发布的新闻稿指出，2023年全球麻疹病例数预计将增加20%，达到1,030万例。这种流行病学的变化直接推动了工业生产，以应对这场青少年健康危机。

同时，旨在强制进行儿童临床试验的有利监管奖励和立法支持正在改变药物研发环境。监管机构已建立相关框架，鼓励企业从仿单标示外且安全性和有效性均已得到验证的治疗方法，这一策略已显着改善了产品的可及性。根据美国小儿科会 (AAP) 2024 年 4 月发布的报告，美国食品药物管理局 (FDA) 在 2023 年更新了超过 75 种药物和 35 种生物製药的儿童标籤。这种监管压力已转化为大规模的商业性成功。赛诺菲在 2024 年 10 月发布的新闻稿中报告称，疫苗销售额达到 38.02 亿欧元（较上年增长 25.5%）。这一显着成长主要得益于新型儿童疫苗的推动。

市场挑战

全球儿童药品市场的扩张受到供应链脆弱性和生产不稳定性严重限制，导致产品供应不稳定，并削弱了医疗服务提供者的信心。当生产瓶颈或品管漏洞影响到关键的儿童製剂时，医疗机构往往被迫限制供应或采用次优的替代疗法。这种营运上的不稳定性不仅危及患者的治疗效果，也为製药公司和医疗服务提供者带来沉重的经济负担，迫使他们将资源用于应对库存危机，而不是用于研发新治疗方法和拓展市场。因此，缺乏可靠的适龄药物供应阻碍了专科药物的推广应用，并限制了该行业的获利潜力。

近期数据显示，专科儿童医疗中心受到的影响尤其严重，凸显了这项挑战的严峻性。儿童医院协会 (CHA) 2025 年的报告指出，儿童医院的药品短缺情况比一般医疗机构高出至少 25%。这种差异凸显了儿童药品供应链的结构性缺陷，製造商对特定配方药品的短缺会导致生产中断，进而引发大范围的市场混乱。持续的药品短缺迫使市场萎缩，相关人员在持续的物流中断中努力维持基本的医疗标准。

市场趋势

儿童特异性基因和细胞疗法的加速发展正在从根本上改变市场格局，将焦点从症状管理转向针对罕见遗传疾病的潜在治癒性治疗。这一趋势的标誌是，越来越多的复杂生物治疗方法获得监管机构核准，旨在纠正婴幼儿的潜在基因缺陷，为曾经被认为无法治癒的疾病带来了新的希望。例如，2024年11月，News-Medical.net网站的一篇报导报导，FDA已核准Keviridy上市，这是第一个用于治疗芳香族L-氨基酸脱羧酶（AADC）缺乏症的基因疗法。此疗法直接注射到大脑。这项核准标誌着以金额为准、单剂量治疗方法的临床成功率和商业性可行性不断提高，吸引了大量投资，并扩大了根治性儿童疾病的范围。

同时，3D列印儿童剂型技术的进步，使得个人化给药成为解决长期以来儿童患者体重和年龄各异，难以准确给药。这项技术能够按需生产适合不同年龄层的製剂，例如速溶片或咀嚼片，与传统的成人药物剂量调整方法相比，显着提高了治疗依从性和安全性。 2024年10月，德克萨斯农工大学宣布，研究人员已获得美国国立卫生研究院（NIH）310万美元的津贴，用于开发一种新型3​​D列印给药系统，以治疗儿童弓形虫病。采用此类积层製造技术可实现精确的剂量滴定和口味掩蔽，有效满足儿童独特的生理和偏好需求。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球儿童药物市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（呼吸系统疾病药物、自体免疫疾病药物、消化器官系统药物、心血管系统药物）
  • 依给药途径（口服、外用、注射、其他）
  • 依最终使用者（医院、专科诊所、居家医疗）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美儿童药物市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲儿童药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区儿童药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲儿童药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲儿童药品市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球儿童药品市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• AstraZeneca PLC
• Pfizer Inc
• Abbott Laboratories Inc
• Amgen Inc
• Novartis AG
• BioMarin Pharmaceutical Inc
• Gilead Sciences, Inc
• F. Hoffmann-La Roche AG
• Jazz Pharmaceuticals Inc
• GlaxoSmithKline Plc
• Sumitomo Pharma Co Ltd
• Johnson & Johnson
• Boehringer Ingelheim GmbH
• Sanofi SA
• Merck & Co. Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Pediatric Drugs Market is projected to expand from USD 139.46 billion in 2025 to USD 194.16 billion by 2031, reflecting a compound annual growth rate of 5.67%. This sector encompasses pharmaceutical formulations that are specifically researched, developed, and authorized for use in infants, children, and adolescents aged zero to eighteen. A primary factor fueling this market is the rising incidence of chronic and infectious diseases among younger populations, which creates a critical need for specialized therapeutic interventions rather than relying on off-label adult medications. Additionally, supportive regulatory frameworks and legislative incentives are actively prompting pharmaceutical companies to prioritize pediatric clinical trials, ensuring a consistent development pipeline of age-appropriate treatments.

Despite these advancements, the industry encounters substantial obstacles related to supply chain vulnerabilities and manufacturing inconsistencies that frequently interrupt patient access to care. These logistical failures often lead to severe shortages of essential medicines, thereby complicating treatment protocols for vulnerable pediatric patients. Highlighting the magnitude of these infrastructure challenges, the American Society of Health-System Pharmacists reported a historic peak of 323 active drug shortages during the first quarter of 2024. Such pervasive scarcity issues represent a significant threat to the sector's stability and have the potential to severely inhibit overall market expansion.

Market Driver

The increasing prevalence of chronic and infectious conditions among children serves as a primary engine for growth within the Global Pediatric Drugs Market. As the burden of disease evolves, there is a heightened requirement for medical formulations that specifically cater to the unique physiological needs of pediatric patients. This necessity is particularly visible regarding the resurgence of preventable infectious diseases, which drives healthcare systems to acquire targeted pediatric immunizations and therapeutics. For instance, a November 2024 press release from the World Health Organization and the U.S. Centers for Disease Control and Prevention noted that worldwide measles cases surged by 20% to an estimated 10.3 million in 2023, an epidemiological shift that directly spurs industrial production to manage health crises in younger demographics.

Simultaneously, the development landscape is being transformed by favorable regulatory incentives and legislative support aimed at mandating pediatric-specific clinical trials. Regulatory authorities have established frameworks that urge companies to shift away from off-label prescribing toward approved therapies that guarantee safety and efficacy, a strategy that is producing tangible improvements in product availability. According to an April 2024 report by the American Academy of Pediatrics, the FDA updated the labeling of over 75 drugs and 35 biologics with pediatric information throughout 2023. This regulatory pressure translates into significant commercial success, as evidenced by Sanofi's October 2024 press release, which reported €3,802 million in vaccine sales-a 25.5% increase attributed largely to novel pediatric immunizations.

Market Challenge

The expansion of the Global Pediatric Drugs Market is severely hampered by supply chain fragilities and manufacturing inconsistencies, which result in unpredictable product availability and diminished confidence among healthcare providers. When production bottlenecks or quality control failures impact essential pediatric formulations, medical facilities are often forced to ration supplies or rely on less optimal therapeutic alternatives. This operational volatility not only endangers patient outcomes but also imposes significant financial strains on pharmaceutical entities and healthcare providers, compelling them to divert resources toward managing inventory crises instead of developing new treatments or expanding market reach. Consequently, the inability to ensure a reliable supply of age-appropriate medications deters the adoption of specialized drugs and restricts the sector's revenue potential.

The gravity of this challenge is emphasized by recent data highlighting the disproportionate impact on specialized pediatric care centers. According to the Children's Hospital Association in 2025, pediatric hospitals encountered at least 25% more drug shortages compared to general healthcare facilities. This disparity underscores the inherent weakness of the pediatric supply chain, where a scarcity of manufacturers for niche formulations can precipitate widespread market disruption during production failures. Such persistent shortages force the market to contract, as stakeholders struggle to uphold basic standards of care in the face of continuing logistical breakdowns.

Market Trends

The market landscape is being fundamentally altered by the acceleration of pediatric-specific gene and cell therapies, which are shifting the focus from symptomatic management to potential cures for rare genetic disorders. This trend is defined by an increase in regulatory approvals for complex biological treatments engineered to rectify underlying genetic defects in infants and children, providing new hope for conditions that were once considered untreatable. For example, a November 2024 article from News-Medical.net highlighted the FDA approval of Kebilidi, the first gene therapy for aromatic L-amino acid decarboxylase (AADC) deficiency, which is administered directly into the brain. This approval illustrates the growing clinical success and commercial viability of high-value, one-time curative therapies that are attracting substantial investment and broadening the range of treatable pediatric indications.

In parallel, the advancement of 3D-printed pediatric dosage forms for personalized dosing is emerging as a vital solution to the persistent difficulty of administering accurate doses to children of diverse weights and ages. This technology facilitates the on-demand production of age-appropriate formulations, such as rapidly dissolving tablets or chewables, thereby significantly enhancing treatment adherence and safety compared to the traditional method of manipulating adult medications. As reported by Texas A&M University in October 2024, researchers received a $3.1 million grant from the National Institutes of Health to create novel 3D-printed delivery systems for treating pediatric toxoplasmosis. The implementation of such additive manufacturing techniques permits precise titration and taste-masking, effectively addressing the specific physiological and preference-based requirements of the pediatric demographic.

Key Market Players

• AstraZeneca PLC
• Pfizer Inc
• Abbott Laboratories Inc
• Amgen Inc
• Novartis AG
• BioMarin Pharmaceutical Inc
• Gilead Sciences, Inc
• F. Hoffmann-La Roche AG
• Jazz Pharmaceuticals Inc
• GlaxoSmithKline Plc
• Sumitomo Pharma Co Ltd
• Johnson & Johnson
• Boehringer Ingelheim GmbH
• Sanofi SA
• Merck & Co. Inc

Report Scope

In this report, the Global Pediatric Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pediatric Drugs Market, By Type

• Respiratory Disorder Drugs
• Autoimmune Disorder Drugs
• Gastrointestinal Drugs
• Cardiovascular Drugs

Pediatric Drugs Market, By Route Of Administration

• Oral
• Topical
• Parenteral
• Others

Pediatric Drugs Market, By End User

• Hospitals
• Specialty Clinics
• Homecare

Pediatric Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Drugs Market.

Available Customizations:

Global Pediatric Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pediatric Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Respiratory Disorder Drugs, Autoimmune Disorder Drugs, Gastrointestinal Drugs, Cardiovascular Drugs)
  • 5.2.2. By Route Of Administration (Oral, Topical, Parenteral, Others)
  • 5.2.3. By End User (Hospitals, Specialty Clinics, Homecare)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Pediatric Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Route Of Administration
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pediatric Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Route Of Administration
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Pediatric Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Route Of Administration
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Pediatric Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Route Of Administration
      • 6.3.3.2.3. By End User

7. Europe Pediatric Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Route Of Administration
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pediatric Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Route Of Administration
      • 7.3.1.2.3. By End User
  • 7.3.2. France Pediatric Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Route Of Administration
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Pediatric Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Route Of Administration
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Pediatric Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Route Of Administration
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Pediatric Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Route Of Administration
      • 7.3.5.2.3. By End User

8. Asia Pacific Pediatric Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Route Of Administration
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Pediatric Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Route Of Administration
      • 8.3.1.2.3. By End User
  • 8.3.2. India Pediatric Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Route Of Administration
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Pediatric Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Route Of Administration
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Pediatric Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Route Of Administration
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Pediatric Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Route Of Administration
      • 8.3.5.2.3. By End User

9. Middle East & Africa Pediatric Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Route Of Administration
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Pediatric Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Route Of Administration
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Pediatric Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Route Of Administration
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Pediatric Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Route Of Administration
      • 9.3.3.2.3. By End User

10. South America Pediatric Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Route Of Administration
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Pediatric Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Route Of Administration
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Pediatric Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Route Of Administration
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Pediatric Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Route Of Administration
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Pediatric Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AstraZeneca PLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc
• 15.3. Abbott Laboratories Inc
• 15.4. Amgen Inc
• 15.5. Novartis AG
• 15.6. BioMarin Pharmaceutical Inc
• 15.7. Gilead Sciences, Inc
• 15.8. F. Hoffmann-La Roche AG
• 15.9. Jazz Pharmaceuticals Inc
• 15.10. GlaxoSmithKline Plc
• 15.11. Sumitomo Pharma Co Ltd
• 15.12. Johnson & Johnson
• 15.13. Boehringer Ingelheim GmbH
• 15.14. Sanofi SA
• 15.15. Merck & Co. Inc

16. Strategic Recommendations

17. About Us & Disclaimer